Who are Treatment of Panlongqi Tablet's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): DEXTROMETHORPHAN HYDROBROMIDE, Mucinex, Dextromethorphan hydrobromide with guaifenesin, Guafenesin tablets, Ivy Leaves Cough Liquid, Guaifenesin Syrup.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/treatment-of-panlongqi-tablet.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-18 · How we verify

Treatment of Panlongqi Tablet — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Treatment of Panlongqi Tablet (Treatment of Panlongqi Tablet) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Expectorant. Area: Respiratory.

phase 3 Expectorant Respiratory Small molecule Live · refreshed every 30 min

Target snapshot

Treatment of Panlongqi Tablet (Treatment of Panlongqi Tablet) — Guang'anmen Hospital of China Academy of Chinese Medical Sciences. Panlongqi Tablet is used to treat chronic bronchitis and asthma by improving lung function and reducing inflammation.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Treatment of Panlongqi Tablet TARGET	Treatment of Panlongqi Tablet	Guang'anmen Hospital of China Academy of Chinese Medical Sciences	phase 3	Expectorant
DEXTROMETHORPHAN HYDROBROMIDE	DEXTROMETHORPHAN HYDROBROMIDE		marketed	Expectorant [EPC]		1984-01-01
Mucinex	guaifenesin	Generic (multiple manufacturers)	marketed	Expectorant [EPC]	Vagal gastric reflex → increased respiratory secretions	1952-01-01
Dextromethorphan hydrobromide with guaifenesin	Dextromethorphan hydrobromide with guaifenesin	Washington University School of Medicine	marketed	Antitussive/expectorant combination	Sigma-1 receptor, NMDA receptor (dextromethorphan); non-specific expectorant mechanism (guaifenesin)
Guafenesin tablets	Guafenesin tablets	American Health Research	marketed	Expectorant
Ivy Leaves Cough Liquid	Ivy Leaves Cough Liquid	Engelhard Arzneimittel GmbH & Co.KG	marketed	Herbal expectorant
Guaifenesin Syrup	Guaifenesin Syrup	Liaoning University of Traditional Chinese Medicine	marketed	Expectorant

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Expectorant class)

Reckitt Benckiser LLC · 2 drugs in this class
American Health Research · 1 drug in this class
EMS · 1 drug in this class
Guang'anmen Hospital of China Academy of Chinese Medical Sciences · 1 drug in this class
Liaoning University of Traditional Chinese Medicine · 1 drug in this class
Reckitt Benckiser Inc. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Treatment of Panlongqi Tablet — Competitive Intelligence Brief. https://druglandscape.com/ci/treatment-of-panlongqi-tablet. Accessed 2026-05-18.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab